Skip to Content

'
William N. William, Jr., MD, M. D. degree

Present Title & Affiliation

N/A

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 432
Houston, TX 77030
Room Number: FC9.3065
Phone: 713-792-6363
Fax: 713-792-1220

Education & Training

Degree-Granting Education

2001 Faculdade de Medicina da Universidade de Sao Paulo, Sao Paula, Brazil, MD, Medicine

Postgraduate Training

2007-2008 Clinical Fellowship, Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, Scott Lippman, MD
2004-2006 Clinical Fellowship, Oncology, Hospital Sirio-Libanes, Sao Paulo, Brazil
2002-2004 Residency, Internal Medicine, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

Board Certifications

2006 Certificate of Completion of Fellowship in Medical Oncology; Specialist in Medical Oncology, Hospital Sirio-Libanes, National Committee of Medical Residency, Brazil
2004 Faculdade de Medicina da Universidade de Sao Paulo; National Committee of Medical Residency, Brazil
2004 Title of Specialist in Internal Medicine; Brazilian Medical Association; Brazilian Society of Internal Medicine

Experience/Service

Academic Appointments

Medical Oncology Fellow, Hospital Sirio-Libanes, Sao Paulo, Brazil, 2004-2006
Resident, Faculdade de Medicine da Universidade de Sao Paulo, Sao Paulo, Brazil, 2002-2004

Selected Publications

Peer-Reviewed Original Research Articles
1. William JR WN, Khuri FR, Fossella FV,Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non-Small Cell Lung Cancer as Frontline and Second-Line Therapy. American Journal of Clinical Oncology. In Press.
2. William JR WN, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Re-Visiting Stage IIIB and IV Non-Small Cell Lung; Analysis of the Surveillance, Epidemiology and End Results Data. Chest. e-Pub 3/2009. PMID: 19318668.
3. Kim, ES, Mauer AM, William JR WN, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS. Phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced non-small cell lung cancer. Cancer, 2/2009. e-Pub 2/2009. PMID: 19208430.
4. William JR WN, Lee JL, ShinDM, Hong WK, Liu S, Lee JJ, Lippman SM, Khuri FR, Kim ES. Phase I trial of weekly topotecan gemcitabine in patients with solid tumors. Am J Clin Oncol 32 (1):15-19, 2/2009. PMID: 19194117.
5. Papadimitrakopoulou VA, Lee JJ, William JR WN,. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 27 (4):599-604, 2/2009. e-Pub 12/2008. PMCID: PMCPMC2645856.
6. Papdimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewsin J, William JR WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WK. Cyclin D1 and Cancer development in laryngeal, premalignancy patients. Cancer prev Res (Phila Pa) 2 (1):14-21, 1/2009. PMID: 19139014.
7. William JR WN, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Fen L, Lotan R, Papadimitrakopoulou VA. High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila Pa) 2 (1):22-26, 1/2009. PMID: 19139014.
8. Papadimitrakopoulou VA, William JR WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK,Nathan CA, Helam JI, Du B. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research 14(7):2095-2101, 2008. PMID: 18381950.
9. William JR WN, Zinner RG, Karp DD, Oh UW,Glisson BS, Phan SC, Stewart DJ. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for treatment of non-small cell lung cancer. Journal of Thoracic Oncology 2(8):745-750, 8/2007. PMID: 17762342.
10. Maluf FC, William JR WN, Rigato O, Menon AD, Parise JR O, Codema MF. Necrotizing fasciitis as a late complication of multimodal treatment for locally advanced head and neck cancer: a case report. Head and Neck 29(7):700-704, 7/2007. PMID: 17252595.
11. William JR WN, Ceddia RB, Curi R. Leptin controls the fate of fatty acids in isolated rat white adipocytes. Journal of Endocrinology 175(3):735-744, 2002.
12. Ceddia RB, William JR WN, Lima FB, Flandin P, Curi R, Giacobino JP. Leptin stimulates uncoupling protein-2 mRNA expression and Krebs cycle activity and inhibits lipid synthesis in isolated rat white adipocytes. European Journal of Biochemistry 267(19:5952-5958, 2000.
13. Ceddia RB, Lopes G, Souza HM, Borba-Murad GR, William JR WN, Bazotte RD, Curi R. Acute effects ofleptin on glucose metabolism of in situ rat perfused liver and isolated hepatocytes. International Journal of Obesity and Related Metabolic Disorders 23(11):1207-1212, 1999.
14. Ceddia RB; William JR WN, Curi R. Comparing effects of leptin and insulin on glucose metabolism in skeletal muscle: evidence for a physiological effect ofleptin on glucose uptake and decarboxylation. International Journal of Obesity and Related Metabolic Disorders 23(1):75-82, 1999.
15. Ceddia RB, William JR WN, Carpinelli AR, Curi R. Modulation of insulin secretion by leptin. General Pharmacology 32(2):233-237, 1999.
16. Ceddia RB, William JR WN, Curi R. Leptin increases glucose transport and utilization in skeletal muscle in vitro. General Pharmacology 31(5):799-801, 1998.
17. Ceddia RB, William Jr WN, Lima FB, Curi R. Leptin inhibits insulin stimulated incorpration of glucose into lipids and stimulates glucose decarboxylation in isolated rat adipocytes. Journal of Endocrinology 158(3):R7-R9, 1998.
18. Ceddia, RB, William Jr WN, Lima FB, Carpinelli AR, Curi R. Pivotal Role of Leptin in Insulin Effects. Brazilian Journal of Medical and Bilogical Research 31(6):715-722, 1998.

Invited Articles
1. William JR WN, Kim ES, Herbst RS. Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Ntat Clin Pract Oncol 6 (3):132-133, 3/2009. e-Pub 1/2009. PMID: 19190590.
2. William JR WN, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 8 (3):213-225. Review, 3/2009. PMID: 19247304.
3. Wiliam JR WN. Estudo de nao-inferioridade em oncologia: o que sao e para que servem. Cancer Hoje 5:5-8, 2007.
4. Ceddia RB, William Jr WN, Curi R. The response of skeletal muscle to leptin. Frontiers in Bioscience 6:D90-D97, 2001. PMID: 11145919.

Editorials
1. William WNGold K, Kim ES. Gefitinib for advanced non-small lung cancer and quality of life: expending and improving treatment options. Annals of Oncology 20:1455-1457, 8/2009.

Abstracts
1. William JR WN, Quanri J, Kim ES, Feng L, Prudkin L, Lee JJ, Behrens C, Wistuba I, Lee HY. Expression of Phospho(p)-AMP-activated protein kinase (AMPK) in lung cancer. IASLC Targeted Therapy of Lung Cancer Meeting, 2/2009.
2. William JR WN, Kies MS, Flossella FV, Gladish G, Heymach JV, Glisson BS, Tse WH, Liu D, Herbst RS, Lippman SM. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). 8th IASLC Targeted Therapy of Lung Cancer Meeting, Santa Monica CA, 2/2008.
3. William JR WN, Lin HY, Lee JJ, Lippman SM, Kim ES. Characteristics and outcome of patients with non-small cell lung cancer (NSCLC) according to ethnicity: a Surveillance Epidemiology and End Results (SEER) database analysis. American Association for Cancer Research, 2008.
4. William JR WN, Jin Q, Kim ES, Feng L, Prudkin L, Lee JJ, Behrens C, Wistuba II, Lee H. Expression of Phospho(p)-AMP-activated protein kinase (AMPK) in lung cancer. Journal of Clinical Oncology 26 (#11085), 2008.
5. Mao L, William JR WN, Lee JJ, Papadimitrakopoulou VA, Lippman SM. Genetic Markers for Selecting High-Risk Population with Oral Premalignancy for the Erlotinib Prevention of Oral Cancer (EPOC) Trial. National Cancer Institute Translational Science Meeting, 2008.
6. Byers LA, Kies M, William JR WN, Hu J, Lee JJ, El-Naggar A, Papdimitrakopoulou V, Myers J, Lippman S, Heymach J. Profiling of cytokines and angiogenic actors (C/AF) in head and neck (HN) cancer correlates circulating biomarkers with clinical outcomes following induction chemotherapy. Journal of Clinical Oncology, ASCO Annual Proceedings 26 (#6005), 2008.
7. William JR WN, Kies MS, Fossella FV, Gladish G, Heymach JV, Glisson BS, Tse WH, Liu D, Herbst RS, Lippman SM. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). Journal of clinical Oncology ASCO Annual Meeting Proceedings 24(18S) (#18098), 2007.
8. Schmerling RA, William JR WN, Belfort FA, Buzaid AC. High dose IL-2 in patients with metastatic melanoma after progression on biochemotherapy 9BioCT). The experience of the Hospital Sirio-Libanes, Brazil. Journal of cCinical Oncology, 2006 ASCO Annual Meeting Proceedings Part 1 24(18S) (#8038), 2006.
9. William JR WN, Schmerling RA, Belfort FA, Fonseca HE, Buzaid AC. Long-term disease-free survival (LTDFS) after biochemotherapy (BioCT) for stage IV melanoma: The experience of the Hospital Sirio-Libanes, Brazil. Journal of Clincal Oncology, 2006 ASCO Annual Meeting Proceedings Part I 24 (18S) (#18013), 2006.
10. Schmerling RA, Maluf FC, William JR WN, Arruda F, Silva JF, Correa S, Abreu CV, Costa FP, Buzaid AC. Pilot study using carboplatin (C), docetaxel (T) and capecitabine (X) before and during radiotherapy (RT) with concurrent boost as an organ-preservation strategy for locally advanced head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology (Meeting Abstracts) 23 (16S) (#5607), 2005.
11. Sumida DH, William JR WN, Ceddia RB, Carvalho CRO; Lima FB, Machado UF, Curi R. Leptin reduces pp185 phosphorylation status and lipogenesis induced by insulin in isolated rat white adipocytes. Diabetes 49 (Suppl 1):A414, 2000.
12. William JR WN, Ceddia RD, Lima FB, Giacobino JP, Curi R. Leptin increases metabolites oxidation in isolated rat adipocytes. Proceedings of the Nutrition Society, 9/1999.
13. William JR WN, Ceddia RB, Lisa FD, Curi R. Leptin alters glucose metabolism in isolated adipocytes. 23rd Congresso Brasilerio de Endocrinologia e Metabolia, Sao Paulo, Brazil, 11/1998.
14. Ceddia RD, William JR WN , Curi. Leptin increases glucose transport and utilization in skeletal msucle in vitro. Kern Aspen Lipid Conference, Aspen Colorado, 8/1997.

Book Chapters
1. William JR WN, Freire FA. Quimioterapia e Radioterapia para o Cancer de Pulmao de Celula Nao-Pequenas Locaimente Avancado. In: Tratmento Multidisciplinar do Can de Pulmao. Chapter 12, 1st. Ed(s) Younes R, Bazaid AC, Katz A. Dendrix Publicacoes: Sao Pablo, Brazil, 112-128, 2008.
2. William JR WN, Pimenta A, Andreotti S, Lima FB,. Obtencao de adipocitos. In: Como cultivar celulas. Chapter 15, 1st. Ed(s) Curi R, Pompeia C, Peres CM. Guanabara-Koogan: Rio de Janeiro, Brazil, 83-88, 2005.
3. William JR WN, Padovese R. Oxidacao de acidos graxos. In: Entendo a gordura: os acidos graxos. Chapter 12, 1st. Ed(s) Curi, R, Pompeia C, Myasaka CK, Procopio J. Manole, Barueri: Sao Paulo, Brazil, 135-159, 2002.

Manuals, Teaching Aids, Other Teaching Publications
1. Marques R, William JR WN, Katz A, Buzaid AC. Cancer de Pulmao Celulas Nao Pequenas: in Manual Pratico de Oncologia Clinica do Hospital Sirio-Libanes, 6th. Ed(s) Buzaid AC, Hoff PM. Dendrix Publicacoes: Sao Paulo, Brazil, Capitulo 4, 62-76, 2008.
2. Katz A, Buzaid AC, William Jr WN, Marques R. Cancer de Pulmao Celulas Pequenas: in Manual Ptratico de Oncologia Clinica do Hospital Sirio-Libanes, 6th. Ed(s) Buzaid AC, Hoff PM. Dendrix Publicacoes: Sao Paulo, Brazil, Capitulo 5, 77-85, 2008.
3. Colli AMF, William JR WN, Santana TR, Bonassa EMA. Guia de Medicamentos: in Manual Pratico de oncologia Clinica do Hospital Sirio-Libanes, 6th. Ed(s) Buzair AC, Hoff PM. Dendrix Publicacoes: Sao Paulo, Brazil, Capitulo 50, 578-624, 2008.
4. William JR WN, Papdimitrakopoulou VA. Identification of high-risk cohorts for head and neck cancer prevention based on tissue markers, LOH and cyclin D1. Ed(s) ASCO. Education Book - ASCO: Chicago, IL, 66-68, 2008.
5. Marques R, William JR WN, Buzaid AC, Yamaguchi N. Cancer de Pulmao Celulas Nao Pequenas, 5th. Ed(s) Buzaid AD, Hoff PM. Dendrix Publicacoes: Sao Paula, Brazil, Capitulo 4, 52-65, 2007.
6. Buzaid AC,William JR WN, Marques R. Cancer de Pulmao Celulas Pequenas: in Manual Pratico de Oncologia Clinica do Hospital Sirio-Libanes, 5th. Ed(s) Buzaid AC, Hoff PM. Dendrix Publicacoes: Sao Paulo, Brazil, Capitula 5, 66-73, 2007.
7. Colli AMF, William JR WN, Santana TR, Bonassa EMA. Guia de Medicamentos: in Manual Pratico de Oncologia Clinical do Hospital Sirio-Libanes, 5th. Ed(s) Buzaid AC, Hoff PM. Dendrix Publicacoes: Sao Paulo, Brazil, Capitulo 48 549-599, 2007.
8. Colli AMF, William JR WN, Santana TR, Bonassa EMA. Apendice: medicamentos mais utilizados em oncologia:, 4th. Ed(s) Buzaid AC, Hoff PM. Dendrix Puliacoes: Sao Paulo, Brazil, Capitulo 48, 506-544, 2006.

Grant & Contract Support

Title: 2009 ASCO Cancer Foundation Young Investigator Award
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2009 - 7/1/2010
 
Title: Randomized Biomarker-driven Study of Pre-operative Cetuximab and/or IMC-A12, an Anti-insulin-like Growth Factor-1 Receptor Monocional antibody in patients with Squamous Cell Carcinoma of the Head and Neck
Funding Source: Commonwealth Foundation/Goodwin
Role: Co-Investigator and Lead Clinical Investigator
Duration: 2008 - 2011
 
Title: Profiling Biomarkers in Head and Nec Cancer Patients Treated Preoperatively with Cetuximab and/or IMC-A12
Funding Source: The University of Texas M. D. Anderson Cancer Center Institute for Personalized Cancer Therapy
Role: Lead Clinical Investigator
Duration: 2008 - 2009
 
Title: SPARC Expression in NSCLC
Funding Source: Abraxis BioScience, Inc.
Role: Co-Investigator
Duration: 2008 - 2009
 
Title: Erlotinib Prevention of Oral Cancer
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Scott M. Lippman, MD
Duration: 2004 - 2010
 
Title: Effects of leptin on glucose transport and metabolism in white rat adipocytes and skeletal muscle
Funding Source: Young Investigators Scholarship, Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
Role: Principal Investigator
Duration: 1997 - 2001

Last updated: 7/21/2009